<span item_type="fundamental" item_id="eaabcd4b54d970c4c0acabd47afb49e7" counter_id="ST/US/ODYY" env="prod"></span><span item_type="announcement" item_id="592597650405592449" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 0.</p><p>EPS: As of FY2026 Q1, the actual value is USD 0.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -207.85 K.</p><p></p><h3>Segment Revenue</h3><p>Odyssey Health, Inc. did not recognize any revenues for the year ended July 31, 2025, or the three months ended October 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1626644/000168316825009080/odyssey_i10q-103125.htm"></span></p><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The net loss for the three months ended October 31, 2025, was - $483,447, compared to - $1,018,906 for the same period in 2024, representing a decrease of 52.6%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1626644/000168316825009080/odyssey_i10q-103125.htm"></span></li><li><strong>General and Administrative Expenses</strong>: These expenses decreased by 47.7% from $579,427 in 2024 to $303,190 in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1626644/000168316825009080/odyssey_i10q-103125.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: For the three months ended October 31, 2025, net cash used in operating activities was - $283,998, compared to - $248,514 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1626644/000168316825009080/odyssey_i10q-103125.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: Net cash provided by financing activities was $290,500 for the three months ended October 31, 2025, compared to $300,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1626644/000168316825009080/odyssey_i10q-103125.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Derivative Liability</strong>: The fair value of the derivative liability was $225,155 as of October 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1626644/000168316825009080/odyssey_i10q-103125.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: Odyssey Health, Inc. plans to license and develop its products, including the CardioMap heart monitoring device and Save-A-Life choking rescue device, upon receiving adequate funding. The company intends to engage third-party research and development firms to assist in product development and apply for trademarks and patents as products advance.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1626644/000168316825009080/odyssey_i10q-103125.htm"></span></li><li><strong>Non-Core Business</strong>: The company entered into a Master Technology and Sub-license Agreement with NeuRX Health, Inc. for exclusive worldwide rights to BreastCheck®, a non-invasive test for breast abnormalities, anticipated to close in January 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1626644/000168316825009080/odyssey_i10q-103125.htm"></span></li></ul><h3>Priority</h3><p>The company emphasizes the need for additional capital to continue operations and execute its business plan, with plans to obtain capital through debt or equity issuances or collaborative arrangements with corporate partners.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1626644/000168316825009080/odyssey_i10q-103125.htm"></span></p>

Odyssey Health, Inc. | 10-Q: FY2026 Q1 Revenue: USD 0